Luye Pharma Group Ltd.
Символ: LYPHF
PNK
0.38625
USDПазарна цена днес
11.6717
Съотношение P/E
-0.2237
Коефициент PEG
1.45B
MRK Cap
- 0.00%
Доходност на DIV
Luye Pharma Group Ltd. (LYPHF) финансови отчети
Баланс
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 30442.4 | 6106.4 | 5544.3 | 5510.3 | ||||||||||||||||||||
balance-sheet.row.short-term-investments | 8899.94 | 1271.7 | 3220.5 | 3072.1 | ||||||||||||||||||||
balance-sheet.row.net-receivables | 9083.1 | 2354.9 | 1783.7 | 1765.1 | ||||||||||||||||||||
balance-sheet.row.inventory | 3262.94 | 827.9 | 772.9 | 746.3 | ||||||||||||||||||||
balance-sheet.row.other-current-assets | 14658.34 | 3009.9 | 4658.7 | 5059.1 | ||||||||||||||||||||
balance-sheet.row.total-current-assets | 47624.65 | 10703.3 | 10785.8 | 10396.7 | ||||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 19926.44 | 5088.5 | 4909.1 | 4594.5 | ||||||||||||||||||||
balance-sheet.row.goodwill | 4170.88 | 1041.9 | 1003.4 | 985.4 | ||||||||||||||||||||
balance-sheet.row.intangible-assets | 25053.85 | 6317.9 | 5984.7 | 5441.8 | ||||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 29224.74 | 7359.8 | 6988.1 | 6427.2 | ||||||||||||||||||||
balance-sheet.row.long-term-investments | 1699.95 | 1968.4 | -2106.4 | -2489.9 | ||||||||||||||||||||
balance-sheet.row.tax-assets | 291.01 | 0 | 113.9 | 133.1 | ||||||||||||||||||||
balance-sheet.row.other-non-current-assets | 4815.04 | 370.7 | 3559.1 | 3520.4 | ||||||||||||||||||||
balance-sheet.row.total-non-current-assets | 55957.17 | 14787.4 | 13463.8 | 12185.4 | ||||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-assets | 103581.81 | 25490.7 | 24249.6 | 22582.1 | ||||||||||||||||||||
balance-sheet.row.account-payables | 2864.67 | 767.2 | 559.9 | 570.9 | ||||||||||||||||||||
balance-sheet.row.short-term-debt | 25899.19 | 5177.3 | 6839.8 | 5263.2 | ||||||||||||||||||||
balance-sheet.row.tax-payables | 565.73 | 0 | 256.3 | 205.1 | ||||||||||||||||||||
balance-sheet.row.long-term-debt-total | 10671.39 | 3228.2 | 2264.7 | 4227.6 | ||||||||||||||||||||
Deferred Revenue Non Current | 264.72 | 0 | 175 | 209.4 | ||||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 94.99 | - | - | - | ||||||||||||||||||||
balance-sheet.row.other-current-liab | 10345.67 | 2193.4 | 2087.5 | 1496.1 | ||||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 13045.19 | 3824.4 | 3720.7 | 6138 | ||||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 223.17 | 70.6 | 38.5 | 42 | ||||||||||||||||||||
balance-sheet.row.total-liab | 52136.22 | 11962.2 | 13207.9 | 13468.2 | ||||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.common-stock | 1944.43 | 486.1 | 457 | 455.8 | ||||||||||||||||||||
balance-sheet.row.retained-earnings | 14005.23 | 0 | 6667.3 | 6061.8 | ||||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 16081.52 | 7885.8 | 254.5 | 534 | ||||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 15700.8 | 4159.3 | 2797.3 | 1436.4 | ||||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 47731.99 | 12531.2 | 10176 | 8488.1 | ||||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 103581.81 | 25490.7 | 24249.6 | 22582.1 | ||||||||||||||||||||
balance-sheet.row.minority-interest | 3713.61 | 997.3 | 865.8 | 625.8 | ||||||||||||||||||||
balance-sheet.row.total-equity | 51445.6 | 13528.5 | 11041.7 | 9113.9 | ||||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 103581.81 | - | - | - | ||||||||||||||||||||
Total Investments | 7732.43 | 3240.1 | 1114.1 | 582.2 | ||||||||||||||||||||
balance-sheet.row.total-debt | 36570.58 | 8405.4 | 9104.5 | 9490.8 | ||||||||||||||||||||
balance-sheet.row.net-debt | 18731.27 | 5166.5 | 6780.8 | 7052.5 |
Отчет за паричните потоци
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 164.46 | 669.8 | -74.6 | 942.2 | |||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 198.81 | 671.3 | 582 | 510.9 | |||||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | -442.9 | -311.9 | -505.9 | |||||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 25.4 | 50 | 50.9 | |||||||||||||||||||
cash-flows.row.change-in-working-capital | 106.97 | 319.8 | -418.1 | -300.3 | |||||||||||||||||||
cash-flows.row.account-receivables | 9.51 | 0 | 0 | 0 | |||||||||||||||||||
cash-flows.row.inventory | -11.37 | -26.6 | -134 | 4.9 | |||||||||||||||||||
cash-flows.row.account-payables | 27.13 | 0 | 0 | 0 | |||||||||||||||||||
cash-flows.row.other-working-capital | 81.7 | 346.4 | -284 | -305.2 | |||||||||||||||||||
cash-flows.row.other-non-cash-items | 425.01 | 410.4 | 355 | 335.7 | |||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 522.9 | 0 | 0 | 0 | |||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -254.27 | -1163.7 | -1541.6 | -1519.9 | |||||||||||||||||||
cash-flows.row.acquisitions-net | -61.6 | -419 | -808.5 | -450.8 | |||||||||||||||||||
cash-flows.row.purchases-of-investments | -725.66 | -3485.9 | -3975.7 | -2859.2 | |||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 747.94 | 2899.5 | 1919 | 4153.8 | |||||||||||||||||||
cash-flows.row.other-investing-activites | -72.36 | 510.8 | 970.7 | 814.2 | |||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -365.95 | -1658.3 | -3436 | 138.2 | |||||||||||||||||||
cash-flows.row.debt-repayment | -274.59 | -8301.9 | -7536.7 | -5896.7 | |||||||||||||||||||
cash-flows.row.common-stock-issued | 127.18 | 189.2 | 1044.5 | 7326.7 | |||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | -78 | |||||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | -175.5 | |||||||||||||||||||
cash-flows.row.other-financing-activites | -41.09 | 8166.9 | 8371.1 | -922.6 | |||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -82.58 | 54.1 | 1878.9 | 254 | |||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | -137.32 | -164.1 | -52.4 | 112.4 | |||||||||||||||||||
cash-flows.row.net-change-in-cash | 207.87 | -114.5 | -1427.1 | 1538 | |||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 2057.96 | 2323.7 | 2438.3 | 3865.4 | |||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 1850.09 | 2438.3 | 3865.4 | 2327.3 | |||||||||||||||||||
cash-flows.row.operating-cash-flow | 522.9 | 1653.8 | 182.4 | 1033.4 | |||||||||||||||||||
cash-flows.row.capital-expenditure | -254.27 | -1163.7 | -1541.6 | -1519.9 | |||||||||||||||||||
cash-flows.row.free-cash-flow | 268.63 | 490.1 | -1359.2 | -486.4 |
Ред за отчет за приходите
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 1755.26 | 6143.1 | 5981.7 | 5200.2 | ||||||||||||||||||||
income-statement-row.row.cost-of-revenue | 546.53 | 1938.9 | 1841.1 | 1803.5 | ||||||||||||||||||||
income-statement-row.row.gross-profit | 1208.73 | 4204.2 | 4140.5 | 3396.7 | ||||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.research-development | 210.33 | - | - | - | ||||||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.other-expenses | 0 | 0.3 | -22 | -62.1 | ||||||||||||||||||||
income-statement-row.row.operating-expenses | 946.96 | 3175.4 | 3186.6 | 3113.9 | ||||||||||||||||||||
income-statement-row.row.cost-and-expenses | 1493.5 | 5114.4 | 5027.8 | 4917.4 | ||||||||||||||||||||
income-statement-row.row.interest-income | 29.71 | 117.1 | 88.7 | 102 | ||||||||||||||||||||
income-statement-row.row.interest-expense | 165.2 | 675.5 | 471.8 | 399.5 | ||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | -63.77 | -187.3 | -545.2 | -461.5 | ||||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0.3 | -22 | -62.1 | ||||||||||||||||||||
income-statement-row.row.total-operating-expenses | -63.77 | -187.3 | -545.2 | -461.5 | ||||||||||||||||||||
income-statement-row.row.interest-expense | 165.2 | 675.5 | 471.8 | 399.5 | ||||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 198.81 | 701.9 | 671.3 | 582 | ||||||||||||||||||||
income-statement-row.row.ebitda-caps | 460.57 | - | - | - | ||||||||||||||||||||
income-statement-row.row.operating-income | 261.77 | 887.4 | 1215 | 387 | ||||||||||||||||||||
income-statement-row.row.income-before-tax | 198 | 700.1 | 669.8 | -74.6 | ||||||||||||||||||||
income-statement-row.row.income-tax-expense | 35.93 | 161 | 86.5 | 70.2 | ||||||||||||||||||||
income-statement-row.row.net-income | 164.46 | 532.6 | 604.8 | -134.4 |
Често задавани въпроси
Какво е Luye Pharma Group Ltd. (LYPHF) общи активи?
Luye Pharma Group Ltd. (LYPHF) общите активи са 25490715000.000.
Какъв е годишният приход на предприятието?
Годишните приходи са 866991490.000.
Какъв е маржът на печалбата на предприятието?
Маржът на печалбата на фирмата е 0.052.
Какъв е свободният паричен поток на компанията?
Свободният паричен поток е 0.052.
Какъв е маржът на нетната печалба на предприятието?
Маржът на нетната печалба е 0.090.
Какъв е общият приход на предприятието?
Общият приход е 0.138.
Каква е Luye Pharma Group Ltd. (LYPHF) нетна печалба (нетен доход)?
Нетната печалба (нетният доход) е 532605000.000.
Какъв е общият дълг на фирмата?
Общият дълг е 8405447000.000.
Какъв е броят на оперативните разходи?
Оперативните разходи са 3175450000.000.
Какъв е броят на паричните средства на фирмата?
Паричните средства на предприятието са 5654804000.000.